Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients 3-65 years of age.~2. Diagnosis of neurofibromatosis (NF1), as outpatients.~3. Presence of clinically significant plexiform neurofibromas (biopsy proven if possible with tissue blocks available); that is tumors that are potentially life threatening or are impinging on vital structures or significantly impair the quality of life from pain or other symptoms.~4. Patients must have measurable disease by magnetic resonance imaging (MRI). Patients must have a Karnofsky or Lansky Performance score of \> 80% and a life expectancy of \> 2 months.~5. Adequate end organ function, defined as the following:~   total bilirubin \< 1.5 x ULN, SGOT and SGPT \< 2.5 x UNL, creatinine \< 1.5 x ULN, ANC \> 1.5 x 109/L, platelets \> 100 x 109/L.~6. Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug.~7. Written, voluntary informed consent.~Exclusion criteria:~1. Patient has received any other investigational agents within 28 days of first day of study drug dosing, unless the disease is rapidly progressing.~2. Patient is \< 5 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed.~3. Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study)~4. Female patients who are pregnant or breast-feeding.~5. Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).~6. Patient has a known brain metastasis. Non-specific CNS changes on MRI/CT characteristic of NF1 are allowed, but not known CNS malignancies.~7. Patient has known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).~8. Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.~9. Patient received chemotherapy within 4 weeks (6 weeks for nitrosourea or mitomycin-C) prior to study entry, unless the disease is rapidly progressing.~10. Patient previously received radiotherapy to greater than 25 % of the bone marrow~11. Patient had a major surgery within 2 weeks prior to study entry.~12. Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Administration of Gleevec (Type: EXPERIMENTAL): Gleevec® will be dosed orally 440 mg/m\^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete